Long-term outcomes following CAR T cell therapy: what we know so far

Kathryn M. Cappell(National Cancer Institute), James N. Kochenderfer(National Institutes of Health)

Nature Reviews Clinical Oncology

April 13, 2023

10.1038/s41571-023-00754-1

Cited by 1,242

Related Papers

Toxicities of chimeric antigen receptor T cells: recognition and management

|Blood|2016|1.4k

Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells

|Blood|2010|387

Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains

|Nature Communications|2020|123

Optimization of anti-CD19 CAR T cell production for treatment of patients with chronic lymphocytic leukemia

|Molecular Therapy — Methods & Clinical Development|2024|5